<div class="pk-crumbs" data-crumbs="[{&quot;label&quot;:&quot;Drugs&quot;,&quot;href&quot;:&quot;README.md&quot;},{&quot;label&quot;:&quot;A11C&quot;,&quot;href&quot;:&quot;atc/A11C.md&quot;},{&quot;label&quot;:&quot;calcitriol&quot;}]"></div>

# calcitriol

- **generic name:** calcitriol
- **ATC codes:** `A11CC04`, `D05AX03`
- **DrugBank:** [DB00136](https://go.drugbank.com/drugs/DB00136) · **PubChem:** [CID 5280453](https://pubchem.ncbi.nlm.nih.gov/compound/5280453)
- **molar mass:** 416.6365 g/mol (C27H44O3) — DrugBank
- **groups:** approved, investigational, nutraceutical

## About

Calcitriol, an active form of vitamin D, is used to treat conditions such as rickets, hyperparathyroidism, and hypoparathyroidism, and is also applied topically as an antipsoriatic for skin conditions like acropustulosis. It is an approved medicine, available as a vitamin D analogue for oral use and as a topical antipsoriatic, and is used fairly widely.

<small>Summary written by `glm-5.3-flash` from [Wikidata Q139195](https://www.wikidata.org/wiki/Q139195) and the WHO ATC classification; not checked by a person.</small>

## Extraction summary

| extracted at | time | popPK e/r/o | PD e/r/o (paper) | PGx e/r/o | tokens in/out | LLM | papers | GROBID/JATS | OA/non-OA | NONMEM |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026-10-05 07:35 | 8:03 | 0/0/0 | 1/0/0 | 0/0/1 | 249,123/12,210 | ollama / qwen3.8:27b-mtp-q8_0 | 16 | 8/30 | 15/1 | 0 |

## popPK records

_not available_

## Pharmacodynamics (PD)

| status | detail | about | model | citation | doi |
|---|---|---|---|---|---|
| <span class="pk-badge pk-badge--green">extracted</span> <span class="pk-badge pk-badge--species" title="The paper reports both human and animal data (from an LLM reading of the title and abstract by gpt-6-luna, p(non-human) 1.00).">human + animal</span> | [García-Quiroz_2016_CAMP](drugs/drug_calcitriol/pd_Garc_a_Quiroz_2016_CAMP.md) | CAMP gene expression ← calcitriol · direct sigmoid Emax (Hill) effect | — | García-Quiroz J et al., Calcitriol stimulates gene expression o…, Journal of biomedical scien… (2016) | [10.1186/s12929-016-0298-4](https://doi.org/10.1186/s12929-016-0298-4) |

## Pharmacogenomics (PGx)

| status | gene | affects | mechanism | detail | citation | doi |
|---|---|---|---|---|---|---|
| <span class="pk-badge pk-badge--neutral" title="the paper links the gene to the drug but states no effect size on a model parameter, so it changes no model.">qualitative</span> <span class="pk-badge pk-badge--orange" title="re-read by gpt-oss:120b (?, agreement 0.25). The first reading is what the record holds.">cross-check: partial</span> | **VDR** | `Q100` — no parameter target — an association/risk finding, not a parameter shift | target | [Yaghooti_2021](drugs/drug_calcitriol/pgx_Yaghooti_2021_VDR_Q100.md) | Yaghooti H et al., The efficacy of calcitriol treatment in…, BMC pharmacology & toxicolo… (2021) | [10.1186/s40360-021-00485-y](https://doi.org/10.1186/s40360-021-00485-y) |

<details class="pk-legend"><summary>What the PGx badges mean — evidence, and whether a model runs</summary><table><tbody><tr><td><span class="pk-badge pk-badge--green">quantitative</span></td><td>the paper gives the effect of each phenotype (or genotype) on a named model parameter — a θ per category.</td></tr><tr><td><span class="pk-badge pk-badge--neutral">qualitative</span></td><td>the paper links the gene to the drug but states no effect size on a model parameter, so it changes no model.</td></tr><tr><td><span class="pk-badge pk-badge--neutral">guideline estimate</span></td><td>the effect comes from a CPIC / DPWG dosing guideline, not from this paper's numbers.</td></tr><tr><td><span class="pk-badge pk-badge--neutral">safety allele</span></td><td>a risk allele for an adverse reaction (an HLA type, G6PD deficiency …): it changes no PK/PD parameter.</td></tr><tr><td><span class="pk-badge pk-badge--orange">needs review</span></td><td>the extraction is incomplete or inconsistent.</td></tr><tr><td><span class="pk-badge pk-badge--red">rejected</span></td><td>not accepted.</td></tr><tr><td><span class="pk-badge pk-badge--green">▶ simulatable</span></td><td>the paper's popPK model runs per phenotype in the browser (Simulation tab); its PGx Modelica model is under Models.</td></tr><tr><td><span class="pk-badge pk-badge--neutral">model only</span></td><td>a PGx Modelica model exists but has no in-browser simulator.</td></tr></tbody></table></details>

<details class="legend">
<summary>What the PGx columns mean</summary>
<table><thead><tr><th>column</th><th>what it holds</th></tr></thead><tbody><tr><td><code>gene</code></td><td>the gene whose variants the record is about. One record per gene, so a paper reporting several genes appears on several rows.</td></tr><tr><td><code>affects</code></td><td>the PK or PD parameter the genotype SHIFTS, as an ontology Q-code plus its name — Q22 = clearance, Q27 = CL/F (apparent clearance), Q32 = Cmax, Q88 = AUC, Q40 = Fab, Q321 = EC50, Q322 = IC50, Q305 = kfm. The record's per-phenotype theta is a multiplier ON that parameter: a poor-metaboliser theta shifts this value, it does not supply one. Two values are NOT parameters — Q100 (NIL) is an association or risk finding with no parameter target, and `safety` is an adverse-reaction risk such as an HLA allele. A PA… id instead of a Q-code marks a record derived from a ClinPGx/PharmGKB guideline lookup rather than read out of the paper.</td></tr><tr><td><code>mechanism</code></td><td>how the gene acts: metabolism, transport, target, formation, safety_allele, or unknown.</td></tr><tr><td><code>detail</code></td><td>the paper stem, linking to the full record page.</td></tr><tr><th colspan="2" style="text-align:left;padding-top:10px">placeholders</th></tr><tr><td><code>not captured</code></td><td>the field is absent from the KB artifact — nothing was recorded. This is NOT the same as zero or empty: the value is unknown, not measured to be nothing.</td></tr><tr><td><code>—</code></td><td>deliberately not shown: the column does not apply to this row.</td></tr><tr><td><code>not verified</code></td><td>the record is not in an accepted state (see the badge and the note above the table); the numbers are shown as extracted, not endorsed.</td></tr></tbody></table>
</details>

## ADME sites

Where this drug is handled, from DrugBank's curated enzymes / transporters / carriers and the KB's PGx genes, mapped to tissue through the ADME gene table. Compare it with other drugs on the [Sites & interactions](sites?drugs=calcitriol) page (add drugs there; the set becomes a link).

| process | tissue | actors (role) | evidence |
|---|---|---|---|
| absorption | small intestine | <sub>named in DrugBank's ADME text</sub> | prose |
| metabolism | kidney | <sub>named in DrugBank's ADME text</sub> | prose |
| metabolism | liver | `CYP3A4` inducer/substrate | DrugBank actor |
| metabolism | small intestine | `CYP3A4` inducer/substrate | DrugBank actor |
| excretion | bile duct | <sub>named in DrugBank's ADME text</sub> | prose |
| excretion | kidney | <sub>named in DrugBank's ADME text</sub> | prose |

<sub>Actors without a tissue in the table: CYP24A1 (inducer), CYP24A1 (substrate), GC (binder), HOXA10 (upregulator), VDR (target).</sub>

<details class="legend">
<summary>Badge legend — what each badge means</summary>
<table><thead><tr><th>badge</th><th>what it means</th></tr></thead><tbody><tr><td><span class="pk-badge pk-badge--green">curated</span></td><td>hand-authored by a person — an exemplar, not an extraction.</td></tr><tr><td><span class="pk-badge pk-badge--green">extracted</span></td><td>the pipeline accepted the record: every closed-form check it could run passed.</td></tr><tr><td><span class="pk-badge pk-badge--green">reviewed — candidate</span></td><td>the reviewer ran the built model against the paper's own reported values and they agree — the best automatic verdict there is.</td></tr><tr><td><span class="pk-badge pk-badge--green">accepted (caveats)</span></td><td>the model replicates the paper, but an advisory check failed — the record page names the caveat under the badge and the drug page shows it under the status.</td></tr><tr><td><span class="pk-badge pk-badge--orange">needs review</span></td><td>extracted, then a check failed or a value looks implausible. The numbers are shown as read, not endorsed.</td></tr><tr><td><span class="pk-badge pk-badge--orange">built, not shipped</span></td><td>a model was built, but a core parameter fell back to a library default, so it is not shipped.</td></tr><tr><td><span class="pk-badge pk-badge--red">rejected</span></td><td>not accepted — the record is not a compartmental model, or nothing usable was extracted.</td></tr><tr><td><span class="pk-badge pk-badge--neutral">not modelled</span></td><td>pipeline state, not a judgement: no model has been built for this record yet (likewise `not simulated`).</td></tr><tr><td><span class="pk-badge pk-badge--stale">stale</span></td><td>the reviewer's verdict predates the latest re-run of the paper — treat the status as out of date, not as current.</td></tr><tr><td><span class="pk-badge pk-badge--green">cross-checked ✓</span></td><td>every independent reader agreed on every compared field. With more than one reader the badge counts them, e.g. 'cross-checked ✓ 2/2'.</td></tr><tr><td><span class="pk-badge pk-badge--orange">cross-check: partial</span></td><td>a reader differs on a non-structural field (a population label, a flag), or the readers do not all agree with each other.</td></tr><tr><td><span class="pk-badge pk-badge--red">cross-check: disputed</span></td><td>at least one reader differs on a structural parameter — a clearance, a volume, ka, a lag. The record still holds the FIRST reading; the disagreement is a signal for a reviewer, never an automatic correction.</td></tr><tr><td><span class="pk-badge pk-badge--species">rat</span></td><td>the data come from an animal (or in-vitro) study, not from people. The record, its model and its simulation are kept — they describe that species.</td></tr></tbody></table>
<p><small>The first badge is the record's <b>status</b> — what the pipeline and the reviewer concluded. A second badge, when present, is the <b>cross-check</b>: whether a model of another family, re-reading the same paper, extracted the same numbers. They are independent — a rejected record can be cross-checked, and a confirmed reading can still fail a plausibility check.</small></p>
</details>

## Coverage

- **PubMed hits:** 9280 matched, 162 returned
- **screened:** 1  ·  **relevant:** 1
- **records:** 0  ·  extracted 0  ·  needs_review 0  ·  rejected 0  ·  stale 0
- **scholar-agent fallback query used:** True

## Full text wanted

_19 paper(s) judged relevant from the abstract, with no full text on disk — paywalled, or the resolver could not reach them. Follow the DOI, then save the PDF into `papers/` as `&lt;save as&gt;.pdf` and re-run the extraction._

| save as | citation | domain | score | DOI | PubMed | why wanted |
|---|---|---|---|---|---|---|
| `Maierhofer_1981.pdf` | Maierhofer WJ et al., Synthesis and metabolic clearance of 1,…, The Journal of clinical end… (1981) | popPK | 8 | [10.1210/jcem-53-3-472](https://doi.org/10.1210/jcem-53-3-472) | [6897931](https://pubmed.ncbi.nlm.nih.gov/6897931) | The study reports compartmental analysis and metabolic clearance of calcitriol (1,25-dihydroxyvitamin D3) in humans, providing quantitative relationships for synthesis and clearance, though specific PK parameters like CL or V are derived from the provided equations rather than listed as single values. |
| `Noh_2020.pdf` | Noh K et al., Noteworthy idiosyncrasies of 1α,25-dihy…, Biopharmaceutics & drug dis… (2020) | pd | 5 | [10.1002/bdd.2223](https://doi.org/10.1002/bdd.2223) | [32319119](https://www.ncbi.nlm.nih.gov/pubmed/32319119) | metadata signals extractable PD data (PK-PD) |
| `Roberts_2019.pdf` | Roberts MS et al., Treatment of Autosomal Dominant Hypocal…, Journal of bone and mineral… (2019) | pd | 5 | [10.1002/jbmr.3747](https://doi.org/10.1002/jbmr.3747) | [31063613](https://www.ncbi.nlm.nih.gov/pubmed/31063613) | metadata signals extractable PD data (EC50) |
| `Ma_2025.pdf` | Ma K et al., Development of Highly Sensitive and Spe…, ACS sensors (2025) | pd | 4 | [10.1021/acssensors.5c00650](https://doi.org/10.1021/acssensors.5c00650) | [40340357](https://www.ncbi.nlm.nih.gov/pubmed/40340357) | metadata signals extractable PD data (EC50) |
| `Muthyalaiah_2024.pdf` | Muthyalaiah YS et al., Exploring the molecular interactions an…, Journal of biomolecular str… (2024) | pd | 4 | [10.1080/07391102.2023.2258993](https://doi.org/10.1080/07391102.2023.2258993) | [37732363](https://www.ncbi.nlm.nih.gov/pubmed/37732363) | metadata signals extractable PD data (IC50) |
| `Tamayo_2017.pdf` | Tamayo M et al., Calcitriol (1,25-dihydroxyvitamin D3) i…, Heart rhythm (2017) | pd | 4 | [10.1016/j.hrthm.2016.12.013](https://doi.org/10.1016/j.hrthm.2016.12.013) | [27989685](https://www.ncbi.nlm.nih.gov/pubmed/27989685) | metadata signals extractable PD data (EC50) |
| `Cusato_2018.pdf` | Cusato J et al., Vitamin D pathway genetic variants are…, Infection, genetics and evo… (2018) | pgx | 8 | [10.1016/j.meegid.2018.02.016](https://doi.org/10.1016/j.meegid.2018.02.016) | [29452294](https://www.ncbi.nlm.nih.gov/pubmed/29452294) | metadata signals extractable PGX data (CYP27B1, PK/PD-context) |
| `He_2023.pdf` | He Q et al., The evolution of folate supplementation…, Journal of translational in… (2023) | pgx | 8 | [10.2478/jtim-2023-0087](https://doi.org/10.2478/jtim-2023-0087) | [37408570](https://www.ncbi.nlm.nih.gov/pubmed/37408570) | metadata signals extractable PGX data (SLC19A1, PK/PD-context) |
| `Ramnath_2013.pdf` | Ramnath N et al., A phase I/II pharmacokinetic and pharma…, Cancer chemotherapy and pha… (2013) | pgx | 8 | [10.1007/s00280-013-2109-x](https://doi.org/10.1007/s00280-013-2109-x) | [23435876](https://www.ncbi.nlm.nih.gov/pubmed/23435876) | metadata signals extractable PGX data (CYP24A1, PK/PD-context) |
| `Wilson_2023.pdf` | Wilson RT et al., Genetic Factors Associated with Absolut…, Cancer epidemiology, biomar… (2023) | pgx | 8 | [10.1158/1055-9965.EPI-22-0797](https://doi.org/10.1158/1055-9965.EPI-22-0797) | [36788426](https://www.ncbi.nlm.nih.gov/pubmed/36788426) | metadata signals extractable PGX data (CYP27B1, PK/PD-context) |
| `Chae_2021.pdf` | Chae YJ et al., Pharmacokinetic Estimation Models-based…, Pharmaceutics (2021) | pgx | 7 | [10.3390/pharmaceutics13020181](https://doi.org/10.3390/pharmaceutics13020181) | [33572963](https://www.ncbi.nlm.nih.gov/pubmed/33572963) | metadata signals extractable PGX data (CYP2B6, PK/PD-context) |
| `Hashiba_2024.pdf` | Hashiba S et al., Cytochrome P450 and UDP-Glucuronosyltra…, Drug metabolism and disposi… (2024) | pgx | 7 | [10.1124/dmd.124.001685](https://doi.org/10.1124/dmd.124.001685) | [38866474](https://www.ncbi.nlm.nih.gov/pubmed/38866474) | metadata signals extractable PGX data (CYP2B6, PK/PD-context) |
| `Abouzid_2023.pdf` | Abouzid M et al., Research Trends of Vitamin D Metabolism…, Genes (2023) | pgx | 5 | [10.3390/genes14010215](https://doi.org/10.3390/genes14010215) | [36672957](https://www.ncbi.nlm.nih.gov/pubmed/36672957) | metadata signals extractable PGX data (CYP27B1) |
| `Bennin_2024.pdf` | Bennin D et al., Loss of 24-hydroxylated catabolism incr…, JBMR plus (2024) | pgx | 5 | [10.1093/jbmrpl/ziae012](https://doi.org/10.1093/jbmrpl/ziae012) | [38577520](https://www.ncbi.nlm.nih.gov/pubmed/38577520) | metadata signals extractable PGX data (CYP24A1) |
| `Cusato_2017.pdf` | Cusato J et al., Association of vitamin D pathway SNPs a…, Pharmacogenomics (2017) | pgx | 5 | [10.2217/pgs-2016-0041](https://doi.org/10.2217/pgs-2016-0041) | [28453395](https://www.ncbi.nlm.nih.gov/pubmed/28453395) | metadata signals extractable PGX data (CYP27B1) |
| `Fahkri_2015.pdf` | Fahkri H et al., Checkpoint kinase Chk2 controls renal C…, Pflugers Archiv : European… (2015) | pgx | 5 | [10.1007/s00424-014-1625-9](https://doi.org/10.1007/s00424-014-1625-9) | [25319519](https://www.ncbi.nlm.nih.gov/pubmed/25319519) | metadata signals extractable PGX data (Cyp27b1) |
| `Gillies_2018.pdf` | Gillies BR et al., Absence of Calcitriol Causes Increased…, Journal of bone and mineral… (2018) | pgx | 5 | [10.1002/jbmr.3217](https://doi.org/10.1002/jbmr.3217) | [28686309](https://www.ncbi.nlm.nih.gov/pubmed/28686309) | metadata signals extractable PGX data (Cyp27b1) |
| `Kirby_2013.pdf` | Kirby BJ et al., Upregulation of calcitriol during pregn…, Journal of bone and mineral… (2013) | pgx | 5 | [10.1002/jbmr.1925](https://doi.org/10.1002/jbmr.1925) | [23505097](https://www.ncbi.nlm.nih.gov/pubmed/23505097) | metadata signals extractable PGX data (Cyp27b1) |
| `Rivero-García_2023.pdf` | Rivero-García P et al., Vitamin D Hydroxylation-deficient Ricke…, JCEM case reports (2023) | pgx | 5 | [10.1210/jcemcr/luad084](https://doi.org/10.1210/jcemcr/luad084) | [37908980](https://www.ncbi.nlm.nih.gov/pubmed/37908980) | metadata signals extractable PGX data (CYP27B1) |

<sub>queue written 2026-10-05T07:29:21.242917+00:00</sub>

## Screened and excluded

| domain | paper | verdict | relevance | extractability | reason |
|---|---|---|---|---|---|
| PGx | Aberger_2024 | not_relevant | 2 | 0 | The paper is a review of treatments for vitamin D toxicity and mentions CYP24A1 polymorphisms as a cause of susceptibility, but it does not report specific pharmacokinetic or pharmacodynamic parameter changes for calcitriol linked to genotypes. |
| PGx | Abouzid_2023 | not_relevant | 0 | 0 | The paper is a bibliometric analysis of publication trends and does not report specific pharmacokinetic or pharmacodynamic data for calcitriol. |
| PGx | Ahn_2016 | not_relevant | 0 | 0 | The paper discusses the biological mechanisms of calcitriol in prostate cancer and mentions enzyme expression levels (CYP24A1, CYP3A4) but does not report a specific gene variant/genotype effect on a pharmacokinetic or pharmacodynamic parameter. |
| PGx | Allegra_2018 | not_relevant | 0 | 0 | The paper reports pharmacogenomic effects on deferasirox pharmacokinetics, not calcitriol. |
| PGx | Amano_2009 | not_relevant | 0 | 0 | The paper is a review discussing the role of calcitriol and VDR polymorphisms in periodontal disease, but it does not report specific pharmacokinetic or pharmacodynamic parameter changes driven by genetic variants. |
| PGx | Bahrami_2020 | not_relevant | 0 | 0 | The paper is a review of Vitamin D's role in cancer prevention and treatment, discussing genetic variants related to Vitamin D metabolism and cancer outcomes, but it does not report pharmacogenomic effects on the pharmacokinetic or pharmacodynamic parameters of calcitriol. |
| popPK | Baroudi_2026 | irrelevant | 0 | 0 | The study focuses on population pharmacokinetic models for tacrolimus, not calcitriol. |
| PD | Baroudi_2026 | not_relevant | 0 | 0 | The paper focuses on population pharmacokinetic (popPK) model selection for tacrolimus and does not report any pharmacodynamic (PD) or exposure-response relationships for calcitriol. |
| popPK | Barry_2026 | irrelevant | 0 | 0 | The study focuses on the pharmacokinetics of vancomycin, not calcitriol. |
| PD | Barry_2026 | not_relevant | 0 | 0 | The paper analyzes vancomycin nephrotoxicity, not calcitriol. |
| popPK | Barzel_2026 | irrelevant | 0 | 0 | The paper is a review of pharmacokinetic models for therapeutic enzymes in lysosomal storage diseases and does not report any data for calcitriol. |
| PD | Barzel_2026 | not_relevant | 1 | 0 | The paper is a review of lysosomal storage diseases and does not contain any data, models, or parameters for calcitriol. |
| PGx | Beka_2022 | not_relevant | 0 | 0 | The study investigates the association between VDR polymorphisms and liver fibrosis susceptibility in HCV patients, not the pharmacokinetics or pharmacodynamics of calcitriol. |
| popPK | Ben-Eltriki_2016 | irrelevant | 0 | 0 | The study is an in-vitro mechanistic investigation of anticancer effects and does not report pharmacokinetic disposition parameters for calcitriol. |
| popPK | Ben-Eltriki_2016_2 | irrelevant | 2 | 3 | The paper is a review that summarizes PK parameters (Cmax, AUC, half-life) from other studies rather than reporting original quantitative disposition parameters or compartmental models for calcitriol. |
| PD | Ben-Eltriki_2016_2 | not_relevant | 2 | 1 | The paper is a narrative review that qualitatively discusses PK/PD interactions and cites preclinical dose-response data (e.g., 10 nM activity) but does not present original numeric PD parameters or an extractable concentration-effect curve. |
| PGx | Ben-Eltriki_2024 | not_relevant | 0 | 0 | The paper is a review discussing the role of CYP enzymes in vitamin D metabolism and melanoma, but it does not report specific pharmacogenomic effects of gene variants on calcitriol PK/PD parameters. |
| popPK | Bodine_1997 | irrelevant | 0 | 0 | The paper describes an in-vitro cell line study focused on estrogen receptor function and bone cell properties, with no pharmacokinetic parameters for calcitriol. |
| PD | Bodine_1997 | not_relevant | 0 | 0 | The paper focuses on estrogen receptor characterization in osteoblasts; while it mentions a dose-dependent response to calcitriol (1,25-dihydroxyvitamin D3), it provides no numeric PD parameters (EC50, Emax, etc.) for calcitriol. |
| popPK | Body_1990 | irrelevant | 0 | 0 | The study investigates calcitonin receptor binding on lymphocytes (in vitro mechanistic study) and does not report pharmacokinetic parameters for calcitriol. |
| PD | Body_1990 | not_relevant | 0 | 0 | The paper reports receptor binding affinity (Kd) and site density for calcitonin, not a pharmacodynamic exposure-response or dose-response relationship for calcitriol. |
| popPK | Bräm_2026 | irrelevant | 0 | 0 | The paper describes a methodological approach for automated pharmacometric modeling using warfarin and generic PK data, with no mention of calcitriol or its specific pharmacokinetic parameters. |
| PD | Bräm_2026 | not_relevant | 0 | 0 | The paper describes a methodological approach for automated pharmacometric modeling using neural ODEs and LASSO, demonstrating it on warfarin PK/PD data, but does not report any PD or exposure-response relationship for calcitriol. |
| popPK | Chae_2021 | irrelevant | 0 | 0 | no_text gate: only 165 chars of text extracted (&lt; 400) |
| PD | Chae_2021 | not_relevant | 0 | 0 | The paper focuses on pharmacokinetic (PK) estimation and CYP induction prediction, not on pharmacodynamic (PD) or exposure-response relationships for calcitriol. |
| PGx | Chae_2021 | not_relevant | 0 | 0 | The paper investigates CYP induction by calcitriol in cell lines, not the effect of a gene variant on calcitriol's PK/PD. |
| popPK | Chen_2014 | irrelevant | 0 | 0 | The study investigates the mechanism of uric acid's effect on 1-alpha-hydroxylase and calcitriol levels, but does not report pharmacokinetic parameters (CL, V, etc.) for calcitriol. |
| PD | Chen_2014 | not_relevant | 2 | 1 | The paper investigates the mechanism of uric acid's effect on 1-alpha-hydroxylase and calcitriol levels, but does not report a pharmacodynamic model or numeric PD parameters (e.g., Emax, EC50) for calcitriol itself. |
| popPK | Cremer_1985 | irrelevant | 0 | 0 | The study evaluates the calciuric (pharmacodynamic) response to calcitriol, not its pharmacokinetic disposition parameters. |
| PGx | Cusato_2017 | not_relevant | 0 | 0 | The paper investigates the effect of vitamin D pathway SNPs on the response to interferon, not on the pharmacokinetics or pharmacodynamics of calcitriol. |
| PGx | Cusato_2018 | not_relevant | 0 | 0 | The paper reports pharmacogenomic effects on sofosbuvir, not calcitriol. |
| popPK | Dahan_2026 | irrelevant | 0 | 0 | The paper is a narrative review of Model-Informed Drug Development for analgesics and does not report pharmacokinetic parameters for calcitriol. |
| PD | Dahan_2026 | not_relevant | 0 | 0 | The paper is a narrative review of MIDD methodologies and does not report specific pharmacodynamic parameters or exposure-response data for calcitriol. |
| PGx | Davis_2024 | not_relevant | 0 | 0 | The paper describes a case of ADHR where iron deficiency modulated the disease phenotype, but it does not report a pharmacogenomic effect on the PK or PD parameters of calcitriol. |
| popPK | Delavenne_2026 | irrelevant | 0 | 0 | The study focuses on the pharmacokinetics of rFIX-FP (Factor IX), not calcitriol. |
| PD | Delavenne_2026 | not_relevant | 0 | 0 | The paper focuses on the pharmacokinetic (PK) validation of a dosing tool for rFIX-FP and does not report any pharmacodynamic (PD) or exposure-response relationship, as the drug's effect (hemostasis) is managed via PK targets rather than modeled PD parameters. |
| popPK | Durna_2020 | irrelevant | 0 | 0 | The study reports pharmacokinetic parameters for doxorubicin, with calcitriol serving only as a co-administered agent to test for interactions, not as the subject drug. |
| popPK | Eisman_1984 | irrelevant | 0 | 0 | The study is an in-vitro mechanistic investigation of calcitriol metabolism in cancer cell lines and does not report quantitative pharmacokinetic parameters such as clearance or volume. |
| PD | Eisman_1984 | not_relevant | 3 | 1 | The paper describes a qualitative biphasic dose-response and metabolic induction but does not provide numeric PD parameters (e.g., EC50, Emax) or quantitative concentration-effect curves in the provided text. |
| popPK | Eleveld_2026 | irrelevant | 0 | 0 | The paper is a methodological comparison of software tools (OpenPMX vs NONMEM) and does not report pharmacokinetic parameters for calcitriol. |
| PD | Eleveld_2026 | not_relevant | 0 | 0 | The paper is a methodological comparison of software tools (OpenPMX vs NONMEM) and does not report any pharmacodynamic or exposure-response data for calcitriol. |
| PGx | Fahkri_2015 | not_relevant | 0 | 0 | The paper investigates the physiological role of the Chk2 gene in endogenous calcitriol synthesis and mineral metabolism, not the pharmacokinetics or pharmacodynamics of exogenous calcitriol as a drug. |
| popPK | Fernández-Barral_2026 | irrelevant | 0 | 0 | The study is an in-vitro mechanistic investigation of calcitriol's effect on chemotherapy cytotoxicity in organoids, not a pharmacokinetic study reporting disposition parameters. |
| PGx | Flynn_2018 | not_relevant | 0 | 0 | The study investigates the intestinal permeability and enzyme interactions of Rauwolfia serpentina using Caco-2 cells, not the pharmacogenomics of calcitriol. |
| PGx | Galyuk_2021 | not_relevant | 2 | 0 | The paper is a hypothesis-generating review discussing the potential role of vitamin D in addiction and mentions that cerebral status may depend on genetic variants, but it does not report specific pharmacogenomic effects on calcitriol PK/PD parameters. |
| PGx | Gandini_2009 | not_relevant | 2 | 0 | The paper is a review and protocol for a future trial discussing VDR polymorphisms and cancer prognosis, but it does not report specific pharmacokinetic or pharmacodynamic parameter changes for calcitriol based on genotype. |
| PGx | García-Quiroz_2012 | not_relevant | 0 | 0 | The paper investigates a drug-drug interaction (astemizole affecting calcitriol's PK/PD) in cell lines, not a pharmacogenomic effect based on human genetic variants. |
| popPK | García-Quiroz_2016 | irrelevant | 0 | 0 | The study is a mechanistic investigation of calcitriol's effect on gene expression (CAMP) in cancer cells and xenografts, reporting EC50 values and calcium levels rather than pharmacokinetic disposition parameters (CL, V, t1/2). |
| popPK | Gardner_1997 | irrelevant | 0 | 0 | The study is an in-vitro mechanistic investigation of calcium signaling in HL60 cells, not a pharmacokinetic study of calcitriol. |
| PD | Gardner_1997 | not_relevant | 2 | 1 | The paper describes a single fixed-dose (10^-7 M) cellular response and qualitative changes in calcium handling, but does not provide a dose-response curve or numeric PD parameters (e.g., EC50 for the drug effect, Emax) for calcitriol. |
| PGx | Gillies_2018 | not_relevant | 0 | 0 | The paper studies the physiological role of calcitriol in bone metabolism in Cyp27b1 null mice, not the pharmacokinetics or pharmacodynamics of calcitriol as a therapeutic drug. |
| popPK | Goldman_1986 | irrelevant | 0 | 0 | The study investigates receptor binding and calcium signaling in HL-60 cells, not the pharmacokinetic disposition parameters of calcitriol. |
| PD | Goldman_1986 | not_relevant | 0 | 0 | The paper reports pharmacology of leukotriene B4 receptors on cells differentiated by calcitriol, but does not report a pharmacodynamic exposure-response or dose-response relationship for calcitriol itself. |
| PGx | Gomaa_2007 | not_relevant | 0 | 0 | The paper describes a homology model and docking study of CYP24A1, but does not report any pharmacogenomic effects of gene variants on calcitriol PK or PD parameters. |
| PGx | Goyal_2014 | not_relevant | 0 | 0 | The paper studies endogenous vitamin D metabolism and CYP24a1 regulation in an animal model, not the pharmacokinetics or pharmacodynamics of exogenous calcitriol administration. |
| popPK | Gram_1996 | irrelevant | 0 | 0 | The study reports pharmacodynamic effects on bone and mineral metabolism markers, not pharmacokinetic disposition parameters for calcitriol. |
| popPK | Grostern_2002 | irrelevant | 1 | 0 | The study focuses on the toxicity and dose-response of a different drug (1alpha-hydroxyvitamin D2) in an animal model, with calcitriol serving only as a comparator, and no quantitative PK parameters for calcitriol are reported. |
| popPK | Gunasekaran_1986 | irrelevant | 0 | 0 | The study is an in-vitro mechanistic investigation of calcium uptake in avian bone, not a pharmacokinetic study reporting disposition parameters for calcitriol. |
| PGx | Harmsen_2008 | not_relevant | 0 | 0 | The paper compares cell lines for CYP3A4 induction modeling and does not report pharmacogenomic effects on calcitriol PK/PD parameters. |
| PGx | Hashiba_2024 | not_relevant | 0 | 0 | The paper evaluates enzyme expression and activity in cell models but does not report pharmacogenomic effects of gene variants on calcitriol PK/PD parameters. |
| PGx | Hayes_1991 | not_relevant | 0 | 0 | The paper studies the metabolism of calcitriol (1,25-dihydroxyvitamin D3) in a specific cell line variant (Ad-HL60) but does not report a pharmacogenomic effect (gene variant/genotype) on PK/PD parameters in humans or a relevant model. |
| PGx | He_2023 | not_relevant | 0 | 0 | The paper discusses folate supplementation and mentions calcitriol only as a factor influencing folate transporter expression, without reporting pharmacogenomic effects on calcitriol's PK or PD parameters. |
| popPK | Hess_1995 | irrelevant | 0 | 0 | The study measures serum calcitriol levels as a biomarker of endogenous synthesis in response to calcium loading, not pharmacokinetic disposition parameters (CL, V, ka) of exogenous calcitriol. |
| PD | Hess_1995 | not_relevant | 2 | 1 | The study reports correlations between urinary calcium excretion and calcitriol levels/changes, but does not provide a dose-response or concentration-effect model with numeric PD parameters (e.g., Emax, EC50) for calcitriol. |
| popPK | Hoeben_2026 | irrelevant | 0 | 0 | The study focuses on the pharmacokinetics of calaspargase pegol (CalPEG), not calcitriol. |
| popPK | Hu_2021 | irrelevant | 0 | 0 | The study investigates the neuroprotective mechanism of calcitriol in Parkinson's disease models (parthanatos pathway) and does not report any pharmacokinetic parameters such as clearance, volume, or half-life. |
| PD | Hu_2021 | not_relevant | 2 | 1 | The paper reports qualitative improvements in cell viability and behavioral tests with fixed doses of calcitriol, but does not provide a concentration-effect curve, dose-response analysis, or numeric PD parameters (e.g., EC50, Emax). |
| popPK | Huang_2026 | irrelevant | 0 | 0 | The paper is a methodological study evaluating an automated PopPK modeling framework (nlmixr2auto) on 22 unspecified datasets and does not report specific PK parameters for calcitriol. |
| PD | Huang_2026 | not_relevant | 0 | 0 | The paper focuses on automated population pharmacokinetic (PopPK) modeling methods and does not report any pharmacodynamic (PD) or exposure-response relationships for calcitriol or any other drug. |
| PGx | Jakob_1995 | not_relevant | 0 | 0 | The paper investigates the regulation of aromatase expression by calcitriol in leukemia cells, not the effect of genetic variants on calcitriol pharmacokinetics or pharmacodynamics. |
| PGx | Jayathilaka_2026 | not_relevant | 2 | 0 | The text is a review of CYP24A1 biology and mentions a pharmacogenetic marker (rs2248359) for dosing, but it does not report specific quantitative PK/PD parameter changes for calcitriol associated with that variant. |
| popPK | Jenkins_2021 | irrelevant | 2 | 0 | The study mentions PK estimates for calcitriol but the provided evidence contains no quantitative disposition parameters (CL, V, etc.) for calcitriol. |
| PGx | Jeong_2024 | not_relevant | 2 | 0 | The paper is a review discussing the association between VDR polymorphisms and Alzheimer's disease risk, not the effect of genotypes on calcitriol pharmacokinetics or pharmacodynamics. |
| popPK | Jia_2026 | irrelevant | 0 | 0 | The study reports population pharmacokinetic parameters for rivaroxaban, not calcitriol. |
| PD | Jia_2026 | not_relevant | 0 | 0 | The paper reports a population pharmacokinetic (PopPK) model for rivaroxaban, not calcitriol, and does not provide a pharmacodynamic (PD) model or numeric PD parameters (e.g., Emax, EC50). |
| popPK | Kang_2026 | irrelevant | 0 | 0 | The study focuses on multiple myeloma drugs (carfilzomib, lenalidomide, etc.) and does not mention calcitriol. |
| PD | Kang_2026 | not_relevant | 0 | 0 | The paper focuses on multiple myeloma drugs (carfilzomib, lenalidomide, etc.) and does not mention calcitriol or report any PD parameters for it. |
| popPK | Karlsen_2026 | irrelevant | 0 | 0 | The paper describes a general framework for benchmarking covariate model building methods using simulated datasets and does not report specific pharmacokinetic parameters for calcitriol. |
| PD | Karlsen_2026 | not_relevant | 0 | 0 | The paper describes a framework for benchmarking covariate model building in population pharmacokinetics (PK) and does not report any pharmacodynamic (PD) or exposure-response relationships for calcitriol. |
| popPK | Kim_2012 | irrelevant | 4 | 1 | The study reports dose-response pharmacodynamics and AUC correlations but lacks specific quantitative PK parameters (CL, V, t1/2) for calcitriol, with concentration data presented only in figures not provided. |
| popPK | Kim_2024 | irrelevant | 0 | 0 | The study is a neurotoxicity/behavioral assay in zebrafish that uses calcitriol as a therapeutic agent to test neuro-restorative effects, and it does not report any pharmacokinetic parameters (e.g., clearance, volume, half-life) for calcitriol. |
| PD | Kim_2024 | not_relevant | 2 | 1 | The study reports a single-dose effect of calcitriol (0.25 µmol) on zebrafish behavior and neuron count, but does not provide a dose-response curve, concentration-effect relationship, or numeric PD parameters (e.g., Emax, EC50). |
| popPK | Kim_2026 | irrelevant | 0 | 0 | The study investigates the pharmacokinetics of bevacizumab (CT-P16), not calcitriol. |
| PD | Kim_2026 | not_relevant | 0 | 0 | The paper reports a population pharmacokinetic (PK) model for bevacizumab (CT-P16) and compares exposure metrics to a published benchmark, but it does not fit a pharmacodynamic (PD) model or report numeric PD parameters (e.g., Emax, EC50) for the drug. |
| PGx | Kirby_2013 | not_relevant | 0 | 0 | The paper investigates physiological regulation of calcitriol levels by PTH and diet in mice, not the effect of a specific gene variant on the pharmacokinetics or pharmacodynamics of exogenous calcitriol as a drug. |
| PGx | Knabl_2017 | not_relevant | 0 | 0 | The paper is a review of VDR polymorphisms in pregnancy disorders and does not report pharmacokinetic or pharmacodynamic parameters of calcitriol. |
| PGx | Kowalówka_2020 | not_relevant | 0 | 0 | The paper is a review of vitamin D status in various diseases and does not report specific pharmacogenomic effects on the PK or PD of calcitriol. |
| PGx | L_2012 | not_relevant | 0 | 0 | The paper is a review discussing the association between Vitamin D status and Parkinson's disease pathology, but it does not report specific pharmacogenomic effects of gene variants on the pharmacokinetics or pharmacodynamics of calcitriol. |
| popPK | Le_2026 | irrelevant | 0 | 0 | The study is an in-vitro mechanistic investigation of vascular reactivity and does not report pharmacokinetic parameters for calcitriol. |
| popPK | Lee_1987 | irrelevant | 0 | 0 | The study is an in-vitro mechanistic investigation of calcitriol-induced differentiation in HL-60 cells and does not report pharmacokinetic disposition parameters. |
| popPK | Li_2026 | irrelevant | 0 | 0 | The paper studies the pharmacokinetics of PF-06804103, an anti-HER2 antibody-drug conjugate, not calcitriol. |
| PD | Li_2026 | not_relevant | 0 | 0 | The paper discusses PF-06804103, not calcitriol. |
| popPK | Li_2026_2 | irrelevant | 0 | 0 | The study reports population pharmacokinetic parameters for the drug gotistobart, not calcitriol. |
| PD | Li_2026_2 | not_relevant | 0 | 0 | The paper reports a population pharmacokinetic (PK) model for gotistobart, not calcitriol, and contains no pharmacodynamic (PD) or exposure-response analysis. |
| PGx | Liao_2014 | not_relevant | 0 | 0 | The paper is a systematic review of clinical trials on calcitriol efficacy and safety in osteoporosis, with no mention of gene variants or pharmacogenomic effects on PK/PD parameters. |
| PGx | Lock_2007 | not_relevant | 0 | 0 | The paper studies physiological changes in Atlantic salmon during smoltification and does not report pharmacogenomic effects of human gene variants on calcitriol PK/PD. |
| PGx | Lu_2023 | not_relevant | 2 | 0 | The paper is a review of vitamin D's role in periodontal disease and mentions VDR polymorphisms in the context of disease severity, but does not report pharmacogenomic effects on the pharmacokinetics or pharmacodynamics of calcitriol. |
| PGx | Luo_2024 | not_relevant | 0 | 0 | The study investigates CYP2D6 genotypes as susceptibility markers for SLE and their association with general clinical indicators (CRP, HGB), but does not report pharmacokinetic or pharmacodynamic parameters for calcitriol. |
| popPK | Ma_2025 | irrelevant | 0 | 0 | no_text gate: only 120 chars of text extracted (&lt; 400) |
| PD | Ma_2025 | not_relevant | 0 | 0 | The paper focuses on the development of genetically encoded biosensors for detection, not on pharmacodynamic modeling or exposure-response analysis. |
| popPK | Maehr_2007 | irrelevant | 0 | 0 | The paper describes the synthesis and biological activity (antiproliferative/renin inhibition) of calcitriol analogs, not pharmacokinetic disposition parameters. |
| popPK | Magdy_2022 | irrelevant | 0 | 0 | The study is a mechanistic investigation of neuroprotective effects in a rat model and does not report any pharmacokinetic parameters for calcitriol. |
| PD | Magdy_2022 | not_relevant | 0 | 0 | The paper is a mechanistic study in a rat model focusing on molecular pathways (Sirt1/NF-kB) and behavioral outcomes, with no pharmacokinetic data, exposure-response analysis, or numeric PD parameters reported. |
| popPK | Miller_1992 | irrelevant | 0 | 0 | The study is an in-vitro receptor binding and mechanistic study on cell lines, not a pharmacokinetic study reporting disposition parameters for calcitriol. |
| popPK | Miraglia_2018 | irrelevant | 0 | 0 | The paper is a review of the immunomodulatory aspects of vitamin D and calcitriol, containing no pharmacokinetic data or quantitative disposition parameters. |
| PD | Miraglia_2018 | not_relevant | 1 | 0 | The text is a qualitative review of vitamin D immunology that mentions a dose-response association with infection risk but provides no numeric PD parameters, concentration-effect curves, or PK/PD modeling for calcitriol. |
| popPK | Mittelman_2006 | irrelevant | 0 | 0 | The paper is a clinical case report on the treatment of hypocalcemia with PTH and does not report pharmacokinetic parameters for calcitriol. |
| PD | Mittelman_2006 | not_relevant | 0 | 0 | The paper reports a dose-response curve for the calcium-sensing receptor (a protein target) in a cell line, not a pharmacodynamic relationship for the drug calcitriol in the patient. |
| PGx | Miyaura_1983 | not_relevant | 0 | 0 | The paper studies the cooperative pharmacodynamic effect of calcitriol and dexamethasone on cell differentiation and mentions resistant clones, but it does not report a specific gene variant/genotype effect on a PK or PD parameter of calcitriol. |
| PGx | Mok_2023 | not_relevant | 0 | 0 | The paper evaluates the antiviral efficacy of calcitriol against SARS-CoV-2 but does not report any pharmacogenomic effects (gene variants) on its pharmacokinetic or pharmacodynamic parameters. |
| popPK | Morales-Guadarrama_2022 | irrelevant | 0 | 0 | The study is an in-vitro mechanistic investigation of drug synergy and cell proliferation, reporting no pharmacokinetic parameters for calcitriol. |
| popPK | Murray_2017 | irrelevant | 0 | 0 | The study is an in-vitro mechanistic investigation of anti-cancer potential and gene expression, not a pharmacokinetic study reporting disposition parameters for calcitriol. |
| PGx | Muthusamy_2018 | not_relevant | 2 | 5 | The paper reports in silico molecular docking and dynamics simulations of VDR variants, not experimental pharmacokinetic or pharmacodynamic parameters of calcitriol. |
| popPK | Muthyalaiah_2024 | irrelevant | 0 | 0 | no_text gate: only 170 chars of text extracted (&lt; 400) |
| PD | Muthyalaiah_2024 | not_relevant | 0 | 0 | The paper focuses on molecular docking and binding affinity of calcitriol with RAGE proteins, not on pharmacodynamic exposure-response or dose-response relationships in a biological system. |
| PGx | Navarro-García_2025 | not_relevant | 0 | 0 | The study investigates the pharmacodynamic effect of calcitriol on PON1 expression in cell lines, but does not report any pharmacogenomic effect (gene variant/genotype) on calcitriol's PK or PD parameters. |
| popPK | Need_1985 | irrelevant | 0 | 0 | The study reports pharmacodynamic effects (calcium absorption rates, bone turnover markers) rather than pharmacokinetic disposition parameters (CL, V, t1/2) for calcitriol. |
| PGx | Negri_2014 | not_relevant | 3 | 0 | The text mentions that VDR BsmI genotype can affect calcitriol response but provides no specific data, effect sizes, or quantitative PK/PD parameters in this excerpt. |
| PGx | Nica-Badea_2021 | not_relevant | 2 | 0 | The paper is a review discussing the association between VDR polymorphisms and cancer risk, not the effect of genetic variants on the pharmacokinetics or pharmacodynamics of calcitriol. |
| popPK | Noh_2020 | irrelevant | 0 | 0 | no_text gate: only 111 chars of text extracted (&lt; 400) |
| PD | Noh_2020 | not_relevant | 1 | 0 | The paper is a commentary on the kinetics of 1α,25-dihydroxyvitamin D3 (calcitriol) and extrapolation from mouse to man, focusing on PK parameters rather than reporting a specific PD or exposure-response model with numeric PD parameters. |
| popPK | Ooi_2026 | irrelevant | 0 | 0 | The study reports population pharmacokinetic parameters for elafibranor and its metabolite GFT1007, not calcitriol. |
| popPK | Orihuela_1999 | irrelevant | 0 | 0 | The study investigates the mechanism of aluminum's effect on intestinal calcium transport and calbindin levels, not the pharmacokinetic disposition parameters (CL, V, t1/2) of calcitriol. |
| popPK | Ozkaya_2017 | irrelevant | 0 | 0 | The paper is an in-vitro transcriptomic study investigating gene expression changes in breast cancer cells, containing no pharmacokinetic parameters for calcitriol. |
| PD | Ozkaya_2017 | not_relevant | 2 | 1 | The study is a transcriptomic analysis at a single fixed dose (IC50) and does not provide a concentration-effect curve or numeric PD parameters (Emax, EC50, slope) for calcitriol. |
| PGx | Papadimitriou_2023 | not_relevant | 0 | 0 | The paper reports clinical outcomes (T1D prevention) and safety (calcium levels) of calcitriol, but does not report pharmacokinetic or pharmacodynamic parameters modified by gene variants. |
| PGx | Pathare_2012 | not_relevant | 0 | 0 | The study investigates the effect of a SPAK gene variant on mineral metabolism parameters (FGF23, phosphate, calcium) but explicitly states that serum calcitriol levels were not significantly different between genotypes, and calcitriol is not the drug being studied for PK/PD changes. |
| PGx | Paucarmayta_2020 | not_relevant | 0 | 0 | The paper investigates the synergistic cytotoxicity of a drug combination in cancer cells and does not report any pharmacogenomic effects (gene variants) on the PK or PD of calcitriol. |
| popPK | Peng_2020 | irrelevant | 0 | 0 | The study models the pharmacokinetics of human amyloid-β40 in rats, using calcitriol only as a pretreatment agent to induce P-glycoprotein, not as the subject drug. |
| popPK | Pesarini_2018 | irrelevant | 0 | 0 | The study is an in-vitro mechanistic investigation of cytotoxicity and apoptosis in mesenchymal stem cells, reporting no pharmacokinetic parameters for calcitriol. |
| popPK | Piatek_2021 | irrelevant | 0 | 0 | The study is an in-vitro mechanistic investigation of calcitriol's biological effects on cell viability and gene expression, not a pharmacokinetic study reporting disposition parameters. |
| PGx | Quesada-Gomez_2022 | not_relevant | 0 | 0 | The paper is a review of calcifediol's use in COVID-19 and does not report any pharmacogenomic effects (gene variants) on PK or PD parameters. |
| PGx | Quinlan_2012 | not_relevant | 0 | 0 | The paper reports clinical growth outcomes in patients with PHEX mutations but does not report pharmacokinetic or pharmacodynamic parameters of calcitriol. |
| PGx | Radványi_2024 | not_relevant | 0 | 0 | The paper investigates the effect of a claudin-3 gene knockout on phosphate homeostasis and calcitriol levels, but does not report pharmacokinetic or pharmacodynamic parameters of calcitriol as a drug (e.g., clearance, volume of distribution, or receptor binding affinity). |
| popPK | Rafique_2019 | irrelevant | 2 | 0 | The study focuses on nanoparticle delivery and pharmacodynamics (cytokine expression) rather than reporting quantitative pharmacokinetic parameters (CL, V, t1/2) for calcitriol. |
| PD | Rafique_2019 | not_relevant | 3 | 1 | The paper reports qualitative anti-inflammatory effects (reduction in cytokines) and biodistribution but does not provide numeric concentration-effect curves, dose-response parameters (Emax, EC50), or a formal PK/PD model fit. |
| PGx | Ramnath_2013 | not_relevant | 0 | 0 | The study explicitly states there was no association between calcitriol pharmacokinetics and CYP24A1 SNPs. |
| popPK | Ribone_2020 | irrelevant | 0 | 0 | The paper is a molecular modeling study focusing on pharmacodynamics and receptor interactions, not pharmacokinetics, and contains no disposition parameters for calcitriol. |
| PD | Ribone_2020 | not_relevant | 0 | 0 | The paper is a molecular modeling study focusing on receptor binding mechanisms and pH effects, not a pharmacokinetic or pharmacodynamic analysis with numeric exposure-response parameters. |
| PGx | Rivero-García_2023 | not_relevant | 0 | 0 | The paper describes a case of CYP27B1 deficiency affecting endogenous vitamin D metabolism and does not report pharmacogenomic effects on the PK or PD parameters of exogenous calcitriol. |
| popPK | Roberts_2019 | irrelevant | 0 | 0 | no_text gate: only 88 chars of text extracted (&lt; 400) |
| PD | Roberts_2019 | not_relevant | 0 | 0 | The paper discusses a calcilytic agent (NPSP795) for hypocalcemia, not calcitriol, and does not report PD parameters for calcitriol. |
| PGx | Ruiz-Ballesteros_2020 | not_relevant | 2 | 0 | The paper is a review of genetic associations with autoimmune diseases and vitamin D levels, not a study reporting pharmacogenomic effects on calcitriol PK/PD parameters. |
| popPK | Sancer_2025 | irrelevant | 0 | 0 | The study is an in-vitro mechanistic investigation of calcitriol's antiproliferative effects on neuroblastoma cells and does not report any pharmacokinetic parameters. |
| popPK | Sarwareddy_2025 | irrelevant | 0 | 0 | The study focuses on in-vitro drug delivery and cytotoxicity of calcitriol, reporting no pharmacokinetic parameters such as clearance, volume, or half-life. |
| PGx | Schmiedlin-Ren_1997 | not_relevant | 0 | 0 | The paper investigates the induction of CYP3A4 expression by vitamin D in Caco-2 cells, not the effect of a genetic variant on calcitriol pharmacokinetics or pharmacodynamics. |
| PGx | Schmiedlin-Ren_2001 | not_relevant | 0 | 0 | The paper investigates the induction of CYP3A4 by calcitriol in cell lines but does not report a pharmacogenomic effect (gene variant) on calcitriol's PK or PD parameters. |
| popPK | Sethuramalingam_2026 | irrelevant | 0 | 0 | The study investigates the pharmacokinetics of asparaginase, not calcitriol. |
| PD | Sethuramalingam_2026 | not_relevant | 0 | 0 | The paper focuses on asparaginase (N-Asp and P-Asp) pharmacokinetics and activity, not calcitriol, and does not report a concentration-effect or dose-response model for calcitriol. |
| popPK | Shionome_1992 | irrelevant | 0 | 0 | The paper is an in-vitro mechanistic study on lipid metabolism in cell lines and does not report any pharmacokinetic parameters for calcitriol. |
| popPK | Slater_1995 | irrelevant | 0 | 0 | The paper describes in-vitro mechanistic studies of protein kinase C activation by 1,25-dihydroxyvitamin D3 and does not report any pharmacokinetic parameters. |
| popPK | Soeorg_2026 | irrelevant | 0 | 0 | The study focuses on the pharmacokinetics of meropenem and colistin/polymyxin B, not calcitriol. |
| PD | Soeorg_2026 | not_relevant | 0 | 0 | The paper focuses on the pharmacokinetic-pharmacodynamic modeling of meropenem and colistin/polymyxin B, not calcitriol. |
| popPK | Sprague_2017 | irrelevant | 0 | 0 | The study focuses on the pharmacokinetics of calcifediol (25-hydroxyvitamin D3), not calcitriol (1,25-dihydroxyvitamin D3), which is only mentioned as a metabolite or comparator. |
| PD | Sprague_2017 | not_relevant | 2 | 1 | The paper is a review of extended-release calcifediol (a calcitriol precursor) and lacks specific numeric PD parameters or extractable exposure-response curves for calcitriol itself. |
| PGx | Sun_2016 | not_relevant | 0 | 0 | The paper investigates the effect of calcitriol on irinotecan metabolism via CYP3A4, but does not report how a specific gene variant or genotype alters the PK/PD of calcitriol itself. |
| popPK | Sutedja_2022 | irrelevant | 0 | 0 | The study is an in-vitro mechanistic investigation of calcitriol's anti-proliferative and apoptotic effects in melanoma cells, reporting no pharmacokinetic parameters such as clearance, volume, or half-life. |
| popPK | Suthahar_2026 | irrelevant | 0 | 0 | The paper is a systematic review of population pharmacokinetic models for 5-fluorouracil, not calcitriol. |
| PD | Suthahar_2026 | not_relevant | 0 | 0 | The paper is a systematic review of population pharmacokinetic (PK) models for 5-fluorouracil, not calcitriol, and contains no pharmacodynamic (PD) or exposure-response analysis. |
| popPK | Sürmelioğlu_2026 | irrelevant | 0 | 0 | The paper is a systematic review of population pharmacokinetic studies for vancomycin, not calcitriol. |
| PD | Sürmelioğlu_2026 | not_relevant | 0 | 0 | The paper is a systematic review of population pharmacokinetic (PopPK) studies for vancomycin, not calcitriol, and focuses exclusively on PK parameters (clearance, volume) and dosing optimization without reporting any pharmacodynamic (PD) or exposure-response models. |
| popPK | Tamayo_2017 | irrelevant | 0 | 0 | no_text gate: only 188 chars of text extracted (&lt; 400) |
| PGx | Tan_2018 | not_relevant | 0 | 0 | The paper investigates the interaction of calcitriol with ABC transporters in cell lines, not the effect of human genetic variants on calcitriol pharmacokinetics or pharmacodynamics. |
| popPK | Tan_2026 | irrelevant | 0 | 0 | The study focuses on the pharmacokinetics of busulfan, not calcitriol. |
| PD | Tan_2026 | not_relevant | 0 | 0 | The paper focuses on busulfan PK and sampling strategies, not calcitriol, and contains no pharmacodynamic or exposure-response analysis. |
| PGx | Theodoropoulos_2003 | not_relevant | 0 | 0 | The study investigates the effect of calcitriol on gene expression in fetal tissue, not the effect of a gene variant on calcitriol pharmacokinetics or pharmacodynamics. |
| popPK | Thompson_2012 | irrelevant | 0 | 0 | The study is an in-vitro mechanistic investigation of cellular differentiation and apoptosis, containing no pharmacokinetic parameters. |
| PGx | Tuey_2021 | not_relevant | 0 | 0 | The study investigates the effect of calcitriol on gene expression in kidney cells, not the effect of a genetic variant on calcitriol pharmacokinetics or pharmacodynamics. |
| PGx | Vattikuti_2004 | not_relevant | 0 | 0 | The paper is a review of vascular calcification pathobiology and does not report pharmacogenomic effects on calcitriol PK or PD parameters. |
| popPK | Wang_2026 | irrelevant | 0 | 0 | The paper focuses on population pharmacokinetic models for polymyxin B, not calcitriol. |
| PD | Wang_2026 | not_relevant | 0 | 0 | The paper focuses exclusively on population pharmacokinetic (PK) modeling of polymyxin B and does not report any pharmacodynamic (PD) or exposure-response relationships for calcitriol. |
| popPK | Wanika_2026 | irrelevant | 0 | 0 | The paper is a methodological study using simulated data to demonstrate a statistical metric (95% CDIRAs) and does not report pharmacokinetic parameters for calcitriol. |
| PD | Wanika_2026 | not_relevant | 0 | 0 | The paper is a methodological case study on uncertainty quantification using simulated PK data and does not report any pharmacodynamic or exposure-response relationship for calcitriol. |
| popPK | Werz_2000 | irrelevant | 0 | 0 | The study focuses on the synthesis and in vitro/in vivo pharmacological activity (receptor binding, metabolic stability, hypercalcemic effect) of calcitriol analogues, not on the quantitative pharmacokinetic disposition parameters (CL, V, t1/2) of calcitriol itself. |
| popPK | Wilhelm_1984 | irrelevant | 0 | 0 | The study investigates receptor binding affinity (Kd) and cooperativity in vitro, not pharmacokinetic disposition parameters like clearance or volume. |
| popPK | Wilhelm_1985 | irrelevant | 0 | 0 | The study is an in-vitro biochemical characterization of receptor binding kinetics and thermodynamics, not a pharmacokinetic study of drug disposition. |
| PD | Wilhelm_1985 | not_relevant | 0 | 0 | The paper describes in vitro biochemical binding kinetics and thermodynamics (Hill coefficient, dissociation rates) of calcitriol to a receptor, not a pharmacodynamic exposure-response or dose-response relationship for a physiological effect. |
| PGx | Wilson_2023 | not_relevant | 2 | 5 | The study examines genetic associations with endogenous calcitriol levels in healthy adults, not the pharmacokinetics or pharmacodynamics of exogenous calcitriol administration. |
| popPK | Winer_2021 | irrelevant | 0 | 0 | The paper is a clinical outcome study comparing PTH 1-34 and calcitriol therapy, reporting pharmacodynamic and clinical endpoints rather than quantitative pharmacokinetic parameters for calcitriol. |
| PD | Winer_2021 | not_relevant | 2 | 1 | The paper reports clinical outcomes and qualitative differences in dose requirements and biomarkers between therapies, but does not provide numeric PD parameters (e.g., Emax, EC50) or a quantitative exposure-response model for calcitriol. |
| popPK | Wu-Wong_2006 | irrelevant | 0 | 0 | The study is an in-vitro mechanistic investigation of gene expression (PAI-1) and does not report any pharmacokinetic parameters for calcitriol. |
| popPK | Wu-Wong_2007 | irrelevant | 0 | 0 | The study is an in-vitro mechanistic investigation of gene expression modulation by calcitriol, not a pharmacokinetic study reporting disposition parameters. |
| popPK | Wu-Wong_2011 | irrelevant | 0 | 0 | The study is an in-vitro mechanistic investigation of gene expression and enzyme activity, not a pharmacokinetic study reporting disposition parameters like clearance or volume. |
| popPK | Wu-Wong_2011_2 | irrelevant | 0 | 0 | The study focuses on the pharmacodynamic effects of a novel VDR modulator (VS-105) in rats, with calcitriol mentioned only as a background comparator, and no pharmacokinetic parameters for calcitriol are reported. |
| popPK | Wu_2026 | irrelevant | 0 | 0 | The study reports population pharmacokinetic parameters for bosutinib, not calcitriol. |
| PD | Wu_2026 | not_relevant | 0 | 0 | The paper focuses exclusively on the population pharmacokinetics (PK) of bosutinib and does not report any pharmacodynamic (PD) or exposure-response relationship for calcitriol or any other drug. |
| popPK | Xajil-Ramos_2026 | irrelevant | 0 | 0 | The study reports pharmacokinetic parameters for tacrolimus, not calcitriol. |
| PD | Xajil-Ramos_2026 | not_relevant | 0 | 0 | The paper reports a population pharmacokinetic (PopPK) model for tacrolimus, not calcitriol, and contains no pharmacodynamic or exposure-response analysis. |
| popPK | Xie_2026 | irrelevant | 0 | 0 | The study focuses on the pharmacokinetics of daptomycin, not calcitriol. |
| PD | Xie_2026 | not_relevant | 0 | 0 | The paper focuses on daptomycin population pharmacokinetics and precision dosing, not calcitriol, and does not report any pharmacodynamic or exposure-response parameters. |
| popPK | Xu_2026 | irrelevant | 0 | 0 | The study focuses on the pharmacokinetics of polymyxin B, not calcitriol. |
| PD | Xu_2026 | not_relevant | 0 | 0 | The paper focuses on pharmacokinetic (PK) exposure prediction (AUC) for polymyxin B using Bayesian and machine learning methods, and does not report any pharmacodynamic (PD) or exposure-response relationships for calcitriol or any other drug. |
| popPK | Zhang_2025 | irrelevant | 0 | 0 | The paper is a systematic review of population pharmacokinetics for imipenem, not calcitriol. |
| PD | Zhang_2025 | not_relevant | 0 | 0 | The paper is a systematic review of population pharmacokinetic (PK) models for imipenem and does not report any pharmacodynamic (PD) or exposure-response relationships for calcitriol. |
| PGx | Zittermann_2003 | not_relevant | 0 | 0 | The study investigates the association between vitamin D status and heart failure, noting that the BsmI genotype did not differ between groups, and does not report a pharmacogenomic effect on calcitriol PK/PD. |
| popPK | Zmijewski_2011 | irrelevant | 0 | 0 | The paper is a mechanistic and in-vitro study on the synthesis and anti-melanoma activity of novel secosteroids, with no pharmacokinetic parameters reported for calcitriol. |
| popPK | Zung_2023 | irrelevant | 0 | 0 | The paper is a genetic and clinical study of a CASR mutation in ADH1, reporting receptor sensitivity (EC50) and clinical outcomes, but contains no pharmacokinetic parameters (CL, V, ka, etc.) for calcitriol. |
| PD | Zung_2023 | not_relevant | 0 | 0 | The paper reports an EC50 for the calcium-sensing receptor (a protein target) in cell assays, not a pharmacodynamic exposure-response relationship for the drug calcitriol in patients. |
| popPK | van_2026 | irrelevant | 0 | 0 | The paper is a systematic review of pharmacokinetics for immunoglobulins (IVIg/SCIg), not calcitriol. |
| PD | van_2026 | not_relevant | 0 | 0 | The paper is a systematic review of pharmacokinetic models for immunoglobulins (IVIg/SCIg) and does not contain any data, analysis, or parameters related to calcitriol. |
| PGx | Åsberg_2010 | not_relevant | 0 | 0 | The paper uses calcitriol as a stimulant for monocytes to diagnose FBPase deficiency, not to study the pharmacokinetics or pharmacodynamics of calcitriol itself. |

---
<sub>Generated by `docs.py` (scholarv2)</sub>
